Albireo Pharma Incの収入
Albireo Pharma Incの収入 は何ですか。
Albireo Pharma Incの収入 は-131.15$です。
収入 の定義は何ですか。
普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
NASDAQのセクタHealth Careにおける収入 の企業と比べるAlbireo Pharma Inc
Albireo Pharma Incは何をしますか。
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Incと類似の収入
- Maravai Lifesciencesの収入 は-132.08$です。
- Pebblebrook Hotel Trustの収入 は-131.77$です。
- iRhythm Technologies Incの収入 は-131.59$です。
- Syros Pharmaceuticalsの収入 は-131.56$です。
- Workhorse Incの収入 は-131.38$です。
- Geronの収入 は-131.28$です。
- Albireo Pharma Incの収入 は-131.15$です。
- China Bestの収入 は-131.06HKD$です。
- Finatis Societe Anonymeの収入 は-131.00€です。
- CNIM S.Aの収入 は-130.92€です。
- Premier Explosivesの収入 は-130.83₨です。
- China Properties Investmentの収入 は-130.82HKD$です。
- Kardan N.Vの収入 は-130.80€です。